ARTICLE | Clinical News
Iclusig ponatinib regulatory update
January 18, 2016 8:00 AM UTC
Ariad said partner Otsuka submitted an NDA to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for Iclusig ponatinib to treat resistant or intolerant chronic myelogenous leukemia (CML) a...